Alesia B. Sadosky, Ph.D., M.P.H., M.B.A., from Global Health Economics and Outcomes Research at Pfizer Inc. in New York City, and colleagues analyzed data from the 2009 Adelphi Disease Specific Programme, in which patients reported the severity of their CLBP condition by answering a single question: "Please rate how your CLBP condition is today." Patient reported severity (mild, moderate, or severe) was assessed with respect to scores on standard patient self-report measures of pain and function.The researchers found that, of the 1,363 survey respondents (49 percent male; mean age, 54.8 years; 52 percent employed at least part time), 28.6, 53.3, and 18.2 percent, respectively, reported mild, moderate, and severe CLBP. As the severity of CLBP increased, there were significant differences observed in increased pain, pain interference with function, and CLBP-linked impairment while working, mainly due to presenteeism. There were higher costs related to lost work productivity resulting from increased work impairment, with estimated annual lost productivity costs of $7,080 per patient for mild CLBP, $16,616 for moderate CLBP, and $25,032 for severe CLBP. CLBP severity was inversely associated with patient satisfaction with pain-related medication.